MANAGEMENT & DISSEMINATION
Leader: Faiez Zannad, CIC Nancy
Objectives and resources
The objectives of this WP are to maximize the impact of the FHU, locally, nationally and internationally, toward the scientific community, health care professionals and users, including the patients.
This will entail:
- bringing more integration between FHU participants, and attract more talents to join the FHU.
- manage project outcomes, reaching out to the various target stakeholders at the national and international level
- interact with the ecosystem and beyond
- durably install CARTAGE as a key player in cardiovascular ageing.
Task 1: Establishing consensus meetings for improvement of clinical guidelines and promoting international networking
Establishment of consensus meetings with permanent multidisciplinary dialogue on the clinical guidelines for CV ageing. We are taking advantage here of the leading positions of FHU members in academic national and international Geriatric (IAGG, EUGMS SFGG), Cardiovascular (ESC, ESH, HFA, SFHTA, GRRC), Nephrology (ERA-EDTA) societies and guideline committees (ESC, EUGMS). One novelty will be the possibility to rely on the CV ageing care unit in WP1 to regularly and durably institute these meetings and discuss the development of evidence-based best practices.
International dissemination: since the year 2000, Nancy CIC-P has been actively promoting dissemination to the scientific and industry community within the unique annual Cardiovascular Clinical Trialists (CVCT) forum and workshops, involving major international institutions (Inserm, NHLBI, EMA and FDA) and industry R&D experts (http://www.globalcvctforum.com/forum/), and dedicated to advancing the field of CV clinical trial science, globally. Since 2005, Nancy-CIC-P also organizes an annual high profile Transatlantic biomarker working group workshop. In addition, since 2003, the coordinator of this FHU organizes every 2 years the "preventive geriatric international meeting". In France many more smaller scale local/national annual meetings (Journée pratique Insuffisance Cardiaque), or regular conferences (EFORVIE - Études et Formation sur le Vieillissement, FAL- forum Alzheimer Lorraine) have become established instruments of local/national integration and dissemination. The FHU members are currently managing no less than 6 websites. Integration will be sought under the banner of a unified CARTAGE website, with more cross-reference both internally and with other major international hubs in the area.
Task 2: Intellectual Property management in link with institutional TTOs
All institutions involved in the FHU have an IP management structure. The usual difficulty encountered in protecting new inventions resides in the distance and the lack of coordination between these institutional TTOs. This task will thus aim at organizing regular meetings of the TTOs enabling them to coordinate their efforts and establish best practices and procedures dedicated to clinicians and scientists for handling new inventions. This would of course take into account any existing Délégation Générale de Gestion which would be largely advertised within the FHU. A successful outcome of this task would be to provide a FHU member with the list of the right persons to contact and an agreed-upon list of all documents requested to support an invention disclosure. This TTO platform would also be beneficial by providing all the tools and best practice procedures to establish a preliminary link for future collaboration (CDA, MTA, etc.). Ultimately, one single institution may act on behalf of the others, which is the case with various ongoing or pending patents managed to date by Inserm Transfert as the lead manager of IP on behalf of CHU and Université de Lorraine. We expect that with the set up of this TTO network, we would considerably accelerate the innovation process among CARTAGE.
Task 3: Establishing networks of collaboration with local SME to broaden the ecosystem on cardiovascular ageing
FHU members have a long standing tradition and highly efficient experience in managing influential national networks. Through the 2 major EY FP7s coordinated in Nancy (F Zannad), HOMAGE and FIBROTAGETS, CARTAGE (has a broad reaching potential, is able to reach out). Participants are also involved in the development of a genuine ecosystem in the Nancy region, creating SME spin-offs of the University of Lorraine (e.g. Innotrem (co-founder S. Gibot), Healthis (co-founder J. Felblinger)). This covers diagnostics as well as telemedicine applications (CardioRenal diagnosticS: cofounders F. Zannad and P. Rossignol) in the Silver Economy field. In order to maximize SME competitiveness, it is of primary importance that they can establish collaborations with high level academics. Within CARTAGE, an important effort will be made to strengthen mutually-beneficial relationships between companies and academia. The head of Incubator Lorrain (which incubated the three aforementioned SMEs) will lead this task. This would be accomplished by inviting the companies to regular public meetings so they can be aware of the ongoing scientific projects and promoting collaborations through national (ANR) or international funded (H2020, ERA-CVD, NIH, etc.) projects. All measures will be taken to ensure the confidentiality of the relationships and avoid conflicts of interest.
Raise the interest of pharmaceutical, medical device and gerontechnology companies interested in the FHU-CARTAGE outcomes Several big pharmaceutical (Novartis, Bayer, etc.) and medical device companies (Boston Scientifics, St Jude, CVRx) have shown a major interest in CV ageing.
It is our intention to build on existing relationships and maximize partnership programs with durable interaction with these major players. Several members of the FHU are eminent influential key opinion leaders to a number of healthcare industry companies. In addition, several members of the CARTAGE consortium have developed significant collaborations with several companies in the fields of telemedicine and new technologies for 18 living assistance in the elderly. The FHU offers high profile expertise and facilities for designing, conducting and analyzing major registry/cohort studies and international clinical trials. Having created the academic CRO “European Drug Development Hub (EDDH)ˮ, we are well positioned to attract durable public private partnerships (PPP) (cf. CVCT forums and workshops, task 1, ongoing clinical research programs (e.g. the health economics trials PRME ESTIM-rHTN with carotid barostimulation in resistant hypertension), under the framework of WP3, with strong interactions with the CIC CV network and NICRCT
(described in task 1): large pharmaceutical, biotechnology and device companies are involved.